Jefferies Lifts Price Target Revises Estimates on ResMed Inc. (RMD)
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $232.15 +1.62%
Rating Summary:
11 Buy, 13 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
11 Buy, 13 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Jefferies analysts raised their price target on ResMed Inc. (NYSE: RMD) from $28 to $34, while maintaining their HOLD rating.
They also raised 2012 revenue and EPS estimates to $1.377B and $1.69 vs. $1.364B and $1.58. For 2013, they raised revenue and EPS estimates to $1.533B and $1.98 vs. prior estimates of $1.529B and $1.82.
ResMed engages in the design, manufacture and marketing of equipment for the diagnosis and treatment of disordered breathing, including obstructive sleep apnea and other respiratory disorders.
According to Jefferies analysts, “RMD posted one its best performances in recent memory driven by continued global mask growth, a strong rebound in NA generators, and improving margins. Company still not seeing impact from competitive bidding and positive HST wave continues to build. While things are looking up, European trends are still mixed, comp bidding is still a question mark, and valuation is full.”
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $32.05 yesterday.
They also raised 2012 revenue and EPS estimates to $1.377B and $1.69 vs. $1.364B and $1.58. For 2013, they raised revenue and EPS estimates to $1.533B and $1.98 vs. prior estimates of $1.529B and $1.82.
ResMed engages in the design, manufacture and marketing of equipment for the diagnosis and treatment of disordered breathing, including obstructive sleep apnea and other respiratory disorders.
According to Jefferies analysts, “RMD posted one its best performances in recent memory driven by continued global mask growth, a strong rebound in NA generators, and improving margins. Company still not seeing impact from competitive bidding and positive HST wave continues to build. While things are looking up, European trends are still mixed, comp bidding is still a question mark, and valuation is full.”
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $32.05 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Deere (DE) PT Raised to $585 at JPMorgan
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
